HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MCC 134

an inverse agonist of pancreatic-type ATP-sensitive potassium channels; structure in first source

Also Known As:

1-(4-(1H-imidazol-1-yl)benzoyl)-N-methylcyclobutanecarbothioamide; MCC-134

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - MCC 134: 2
Organic Chemicals: 133
- Amides: 2428
  - Thioamides: 85
    - MCC 134: 2
- Sulfur Compounds: 278
  - Thioamides: 85
    - MCC 134: 2

Experts

1.	Kolár, F: 1 article (01/2005)
2.	Neckár, J: 1 article (01/2005)
3.	Ostádal, B: 1 article (01/2005)
4.	Akao, Masaharu: 1 article (03/2003)
5.	Bolli, Roberto: 1 article (03/2003)
6.	Guo, Yiru: 1 article (03/2003)
7.	Jo, Su-Hyun: 1 article (03/2003)
8.	Marbán, Eduardo: 1 article (03/2003)
9.	Murata, Mitsushige: 1 article (03/2003)
10.	O'Rourke, Brian: 1 article (03/2003)

Related Diseases

1.	Ischemia 01/01/2005 - "MCC-134 was administered intravenously 10 min before ischemia and 5 min before reperfusion in a total dose of 0.3 mg/kg or 3 mg/kg divided into two equal boluses. " 03/04/2003 - "MCC-134 also attenuated the effect of ischemic preconditioning against myocardial infarction in mice, consistent with the results of cell-pelleting ischemia assays. " 03/04/2003 - "In cell-pelleting ischemia assays, coapplication of MCC-134 with diazoxide abolished the cardioprotective effect of diazoxide, whereas MCC-134 alone did not alter cell death. "
2.	Myocardial Infarction 03/04/2003 - "MCC-134 also attenuated the effect of ischemic preconditioning against myocardial infarction in mice, consistent with the results of cell-pelleting ischemia assays. "
3.	Infarction (Infarctions) 01/01/2005 - "Both doses of MCC-134 completely abolished the antiarrhythmic protection (score 2.4+/-0.7 and 2.5+/-0.5, respectively) but only the high dose blocked the infarct size-limiting effect of chronic hypoxia (54.2+/-3.7 %). "
4.	Hypoxia (Hypoxemia) 01/01/2005 - "Both doses of MCC-134 completely abolished the antiarrhythmic protection (score 2.4+/-0.7 and 2.5+/-0.5, respectively) but only the high dose blocked the infarct size-limiting effect of chronic hypoxia (54.2+/-3.7 %). " 01/01/2005 - "MCC-134, a blocker of mitochondrial and opener of sarcolemmal ATP-sensitive K+ channels, abrogates cardioprotective effects of chronic hypoxia." 01/01/2005 - "We examined the effect of MCC-134, a novel inhibitor of mitochondrial ATP-sensitive K(+) (mitoK(ATP)) channels and activator of sarcolemmal ATP-sensitive K(+) (sarcK(ATP)) channels, on cardioprotection conferred by adaptation to chronic hypoxia. "

Related Drugs and Biologics

1.	Diazoxide (Hyperstat)
2.	Adenosine Triphosphate (ATP)
3.	mitochondrial K(ATP) channel